Stock Price Quote

PFIZER LTD.

NSE : PFIZERBSE : 500680ISIN CODE : INE182A01018Industry : Pharmaceuticals & DrugsHouse : Pfizer - MNC
BSE4034.40-27 (-0.66 %)
PREV CLOSE ( ) 4061.40
OPEN PRICE ( ) 4050.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1256
TODAY'S LOW / HIGH ( )4010.85 4079.15
52 WK LOW / HIGH ( )3406.95 4662.35
NSE4036.65-24 (-0.59 %)
PREV CLOSE( ) 4060.65
OPEN PRICE ( ) 4074.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 11436
TODAY'S LOW / HIGH( ) 4023.30 4077.70
52 WK LOW / HIGH ( )3408 4660
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 21-11 1950
Management Info
Pradip Shah - Chairman Meenakshi Nevatia - Managing Director
Registered Office

Address The Capital, 1802/1901,Plot No. C-70, G Block,Bandra Kurla Complex, Bandra (East),
Mumbai,
Maharashtra-400051

Phone 022 6693 2000

Email contactus.india@pfizer.com

Website www.pfizerltd.co.in

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

31Oct Announcement under Regulation 30 (LOD
Appointment of Mr. P Rengan as Executive Director - Plant Operations - P..
18Aug Pfizer informs about change in managem
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..
20Jul Pfizer informs about loss of share cer
Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (..
20Jun Pfizer informs about loss of share cer
Pursuant to Regulation 39 (3) and other applicable regulations of SEBI (..
16May Pfizer reports marginal rise in Q4 net
Pfizer has reported results for fourth quarter (Q4) and year ended March..

Financials

in Millions
QTR Sep 23 ANNUAL 23
Net Profit1489.66239.3
Gross Profit 2005.2 8240.1
Operating Profit 2186.89099.1
Net Sales 5752.124247.6

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  5715.55 (0.78%)
M.Cap ( in Cr)95335.50
Concord Biotech (BSE)
peergroup  1285.75 (2.51%)
M.Cap ( in Cr)13451.03
Ajanta Pharma (BSE)
peergroup  1948.40 (1.43%)
M.Cap ( in Cr)24533.41
Mercury Laboratories (BSE)
peergroup  800.00 (3.07%)
M.Cap ( in Cr)96.00
Ipca Laboratories (BSE)
peergroup  1121.30 (2.15%)
M.Cap ( in Cr)28447.85

Shareholding Pattern

FI/BANKS/INSURANCE 7.58%
MUTUAL FUNDS/UTI 7.39%
PROMOTERS 63.92%
NON-INSTITUTION 18.25%
GOVERNMENT 0%
FII 0%

About Pfizer Ltd.

Pfizer Ltd. was incorporated in the year 1950. Its today's share price is 4034.4. Its current market capitalisation stands at Rs 18456.46 Cr. In the latest quarter, company has reported Gross Sales of Rs. 25602.7 Cr and Total Income of Rs.25258.1 Cr. The company's management includes Milind Patil, Uday Khanna, Sunil Lalbhai, Meenakshi Nevatia, Meena Ganesh, Pradip Shah, Prajeet Nair.

It is listed on the BSE with a BSE Code of 500680 , NSE with an NSE Symbol of PFIZER and ISIN of INE182A01018. It's Registered office is at The Capital, 1802/1901,Plot No. C-70, G Block,Bandra Kurla Complex, Bandra (East)Mumbai-400051, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are AF Ferguson & Co, BSR & Co, BSR & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.